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Background and objective: Nua kinase 1 (NUAK1) was identified in multigene signa-
tures of survival and suboptimal debulking in high-grade serous ovarian cancer (HGSOC). 
This study investigates the individual clinical and biologic contributions of NUAK1 in 
HGSOC patients and cell lines.
Methods: Public transcript expression, clinical, and outcome data were used to interro-
gate the relationship between NUAK1 and clinicopathologic factors and patient outcomes 
including progression-free survival (PFS) and molecular subtypes using logistic and Cox 
modeling. Analysis of NUAK1 transcript expression was performed in primary tumors 
from 34 HGSOC patients with < or ≥2 years PFS. The impact of silencing NUAK1 by 
RNA interference (RNAi) on the migratory potential and chemosensitivity of SOC cells 
was assessed in vitro.
results: Elevated NUAK1 transcript expression was associated with worse PFS (hazard 
ratio = 1.134), advanced stage (odds ratio, OR = 1.7), any residual disease (OR = 1.58), 
and mesenchymal disease subtype (OR =  7.79 ±  5.89). Elevated NUAK1 transcript 
expression was observed in HGSOC patients with < vs. ≥2  years PFS (p <  0.045). 
RNAi-mediated silencing of NUAK1 expression attenuated migration of OV90 and E3 
HGSOC cells in vitro, but did not modulate sensitivity to cisplatin or paclitaxel.
conclusion: Elevated NUAK1 was associated with poor survival as well as advanced 
stage, residual disease after cytoreductive surgery and mesenchymal molecular sub-
type. NUAK1 impacted migration, but not chemosensitivity, in vitro. Additional studies 
are needed to further develop the concept of NUAK1 as a clinically deployable biomarker 
and therapeutic target in HGSOC.
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inTrODUcTiOn
High-grade serous ovarian cancer (HGSOC) will comprise 
approximately 70% of the estimated 21,290 new diagnoses of 
ovarian malignancy in the US in 2016 (1, 2). Since HGSOC is 
also responsible for 90% of ovarian cancer cases with peritoneal 
carcinomatosis, it will be responsible for the vast majority of 
the 14,180 expected deaths from ovarian cancer in 2016 (1, 2). 
Though HGSOC is an ominous diagnosis, considerable variation 
exists between patients in terms of the time from diagnosis to 
disease progression and cancer death. Some patients progress 
relatively quickly within the first 1–2 years, while others may take 
between 5 and 10  years to succumb to their cancer. Common 
features of shorter progression-free survival (PFS) and overall 
survival (OS) in HGSOC patients include older age, advanced 
stage and dissemination of disease into the upper abdominal cav-
ity at diagnosis, and presence of residual tumor following cytore-
ductive surgery (1, 3, 4). Recently, genomic studies of HGSOC 
have confirmed the dominant alterations in p53, common defects 
in homologous recombination, and identified novel gene expres-
sion patterns that correlate with OS, PFS, suboptimal debulking, 
and molecular subtypes (5–8) augmenting clinicopathologic 
characteristics that inform on HGSOC outcomes and enhancing 
chemotherapy and surgical planning.
The overexpression of adenosine monophosphate-related 
kinase 5 (ARK5), also known as novel (nua) kinase family 1 
(NUAK1) (9, 10), exemplifies a transcript whose elevated abun-
dance has been identified in several gene expression signatures 
correlated with inferior survival and suboptimal residual tumor 
(>1 cm) after cytoreductive surgery in HGSOC (5, 6). The rela-
tionship between NUAK1 and either PFS or molecular subtypes 
in HGSOC has not yet been reported. In addition, the association 
between NUAK1 and OS in HGSOC patients has not yet been 
validated. NUAK1 is a downstream effector of Akt and is acti-
vated in response to cellular hypoxia and nutrient starvation (10, 
11). Activation of NUAK1 leads to enhanced proliferation, inva-
sion, and metastatic potential in lung, colorectal, and pancreatic 
adenocarcinoma cells (10, 11). There is, however, a paucity of 
data detailing possible mechanisms responsible for the observed 
poor survival among HGSOC patients with elevated NUAK1 
expression. Recent efforts have described small-molecule inhibi-
tors targeting NUAK1/2 that have demonstrated in vitro efficacy 
against tumor cell proliferation and migratory potential, high-
lighting the possibility that NUAK1 may represent a therapeutic 
target (12).
This investigation details the significant associations between 
elevated NUAK1 transcript expression and poor outcomes 
in HGSOC, documenting the relationship with PFS and the 
mesenchymal subtype, and validates previous associations with 
OS. Elevated NUAK1 transcript expression and shorter PFS was 
validated by quantitative PCR analyses in ovarian cancer tissue 
from HGSOC patients with short vs. long disease progression. We 
further demonstrate that knockdown of NUAK1 does not modu-
late chemosensitivity, but does confer a pro-migratory phenotype 
to HGSOC cells in vitro. These analyses defined a biologically and 
clinically compelling combination of biomarkers that when both 
expressed at high levels indicated worse PFS and OS in HGSOC 
patients and flagged the molecular subtypes with the worst clini-
cal outcome (mesenchymal and proliferative).
MaTerials anD MeThODs
Biostatistical analyses of nUaK1 in Public 
Patient-Derived high Throughput and 
clinical Outcome Data
Public Dataset Acquisition
Tumor transcript expression data were acquired in 
the R open source  statistical computing and graph-
ing environment version 3.1.2 using the Bioconductor1 
packages FULLVcuratedOvarianData_1.0.1  and curatedOvarian-
Data_1.3.4., TCGA’s data portals,2 the Memorial Sloan Kettering 
Cancer Center (MSKCC) Cancer Genomics Data Servers using 
the CDGS package in R, and the Gene Expression Omnibus 
(GEO) repository3 (5, 13–15). All downloaded data sets were 
derived from hybridization-based transcriptomic data generated 
from fresh frozen primary tumor and were screened for inclu-
sion criteria. Only cases of ovarian tumor from serous histology 
with complete stage information (I, II, III, IV, early, or late), with 
available vital status (dead or alive), and survival time in months 
from the date of diagnosis were included in the analysis (Table 1). 
Some cases also had PFS data, age at diagnosis, suboptimal dis-
ease status, any residual disease status, BRCA1/2 status, and/or 
up to three distinct molecular subtype classifications. Previously 
described duplications of data within the data sets were removed, 
and any perceived duplications within a data set or between data 
sets from the same collaborations were removed (16).
Statistical Analysis of Expression Data
Eligible cases from seven Affymetrix data sets were combined 
(GSE26712, GSE14764, GSE3149, GSE18520, GSE9891, 
GSE26193, and TCGA) (5, 17–22). Prior to any statistical analy-
ses, the seven merged data sets were combat-corrected to correct 
for any between-experiment batch effects. Batch correction was 
completed with the Surrogate Variable Analysis package from 
Bioconductor in “R” (15). We further validated our findings 
correlating elevated NUAK1 and OS in an independent HGSOC 
cohort derived from cross-microarray platform, i.e., Agilent, data 
(GSE53963) (8).
Transcript abundance levels of the following probesets in 
the discovery, Affymetrix cohort (NUAK1_204589_at) and 
the validation, Agilent cohort (NUAK1_A_23_P348257) were 
analyzed in univariate Cox logistic regression models for rela-
tionship with OS using Bioconductor package survival_2.37-7 
(15). Impact on PFS was similarly calculated in a subset of 
cases in which time to first disease recurrence information 
was available. Log-rank analyses with Kaplan–Meier (KM) 
plots were generated for OS and PFS comparing survival based 
on low (≤median) vs. high (>median) probe set expression 
1 http://www.bioconductor.org/. 
2 https://tcga-data.nci.nih.gov/tcga/findArchives.htm or https://tcga-data.nci.nih.
gov/tcga/tcgaDownload.jsp. 
3 http://www.ncbi.nlm.nih.gov/geoprofiles. 
TaBle 1 | clinicopathologic characteristics of public transcript datasets analyzed.
author  
accession #
aBonome 
gse26712
aDenkert 
gse14764
aDressman 
gse3149
aMok  
gse18520
aTothill  
gse9891
aMateescu 
gse26193
aTcga bKonecny 
gse53963
Total
Reference # (17) (18) (19) (21) (22) (20) (5) (8) –
Cases 185 68 116 53 216 79 545 174 1,436
Stage
I–II – 3 1 – 29 17 42 8 100
III 149 64 98 53 169 48 421 126 1,128
IV 36 1 17 – 18 14 82 40 208
Age
<60 70 – – – 119 – 288 63 540
 ≥60 112 – – – 97 – 257 111 577
No data 3 68 116 53 – 79 – – 319
Residual disease
No gross
90
–
62 53
84 – 115 – 199
<1 cm – 41 – 244 – 490
≥1 cm 95 – 54 – 65 – 134 – 348
No data – 68 – – 26 79 52 174 399
Vital status
Dead 129 19 67 41 94 60 281 153 844
Alive 56 49 49 12 122 19 264 21 592
aAuthor name – discovery cohort.
bAuthor name – validation cohort.
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values. All tests were two-sided and significance was set at 
p <  0.05. Odds ratio calculations were performed by logistic 
regression modeling using the glm function in R statistical 
computing software (x64 ver 3.2.0) correlating high NUAK1 
expression with advanced disease stage, age at diagnosis, having 
microscopic residual disease, i.e., R0, following cytoreductive 
surgery, having wild-type BRCA1 and relative to previously 
published classifications of patients exhibiting mesenchymal-
like, differentiated-like,  immunoreactive-like, or proliferative-
like ovarian cancer molecular disease subtypes (5, 7, 8).
Quantitative Pcr Validation of nUaK1 
expression levels relative to 
Progression-Free survival
Cohort Selection and Laser-Microdissection
De-identified formalin-fixed, paraffin-embedded (FFPE) tissue 
blocks from patients with advanced-stage HGSOC (n = 34) and 
clinical histories denoting PFS times of ~4.6–77.9 months were 
obtained from INOVA Fairfax Hospital under an IRB-approved 
protocol. Eight micrometer thick sections of each tissue were cut 
by microtome, placed onto PEN membranes (Leica Microsystems, 
Wetzlar, Germany), and 18.0 mm2 of tissue was laser microdis-
sected to selectively capture (>  95% purity) cells of tumor cell 
populations. Laser-microdissected cells were collected directly 
into microcentrifuge tubes containing 45.0  μL of digestion 
buffer, i.e., RecoverAll Total Nucleic Acid Isolation Kit for FFPE 
(AM1975, Thermo Fisher/Invitrogen).
Quantitative PCR Analyses
Total RNA was extracted from equivalent amounts of LMD mate-
rial using RecoverAll Total Nucleic Acid Isolation Kit for FFPE 
(AM1975, Thermo Fisher/Invitrogen), and cDNA was prepared 
from 100 ng of total RNA by reverse transcription using the High 
Capacity cDNA Reverse Transcription kit (Invitrogen). NUAK1 
(Hs00934234_m1) and CDKN1B (Hs00153277_m1) TAQMAN 
assays were obtained from Invitrogen. cDNA pre-amplification 
was performed using TAQMAN gene expression assays diluted 
1:5 and the TAQMAN PreAmp Master Kit for 10  cycles. 
Quantitative PCR was performed using TAQMAN gene expres-
sion master mix on 10% of total pre-amplified cDNA for 50 cycles 
(GeneAmp 9700 PCR system, Applied Biosystems). Endpoint 
data were assembled by comparison of Delta-Ct values for gene 
of interest vs. corresponding CDKN1B Delta-Ct values, a gene 
previously reported as a stable pre-amplification and reference 
control for qPCR analyses of FFPE tissues [Applied Biosystems 
(23)], for each patient sample. Data reflects triplicate, technical 
replicate analyses.
assessing the role of nUaK1 in 
regulating the chemosensitivity of OV90 
cells and cell Migration in 
chemosensitive (OV90) and resistant (e3) 
Ovarian cancer cells
Cell Culture and Reagents
OV90 cells were obtained commercially (ATCC, Manassas, VA, 
USA) and the chemoresistant, HGSOC cell line (E3), previously 
described (24), was generated in-house from tumor tissues 
harvested from a patient-derived xenograft mouse established 
from a chemorefractory ovarian cancer patient. Cell lines were 
maintained in complete DMEM-F12 media (ATCC) and sup-
plemented with 10% FBS and 1% penicillin/streptomycin (Pen/
Strep). Cell line identities were authenticated by STR testing and 
determined to be mycoplasma free. Cisplatin and paclitaxel were 
obtained from Sigma-Aldrich.
Small Interfering RNA (siRNA) Transfections and 
Migration Assays
Cell lines were plated in replicates at equivalent densities on day 
1, transfected with 125 nM of a scrambled, non-targeting siRNA 
FigUre 1 | elevated nUaK1 expression is associated with poor overall and progression-free survival in high-grade serous ovarian cancer patients. 
Kaplan–Meier (KM) plots of NUAK1 transcript expression and cox regression results of categorized NUAK1 expression relative to patient survival. (a) Overall survival 
(OS, NUAK1 continuous multivariate HR = 1.19, p-value = 3.03E−07, n = 1,262). (B) Progression-free survival (PFS, NUAK1 continuous multivariate HR = 1.42, 
p-value = 2.19E−05, n = 802). (c) Cox regression results of categorized NUAK1 levels versus OS. (D) Cox regression results of categorized NUAK1 levels versus 
PFS. p-value insets derived from Log-Rank analyses.
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(ON-TARGETplus Non-targeting Pool, GE Dharmacon, product 
# D-001810-10-50) or NUAK1-specific siRNA (ON-TARGETplus 
NUAK1 SMARTpool siRNA, GE Dharmacon, product # L-004931- 
01-002020) on day 2 and incubated for 48  h. One set of RNA 
interference (RNAi)-transfected cells were harvested for immu-
noblot evaluation, while the remaining set was re-plated to 
achieve confluency 24  h later. Equivalently sized wounds were 
then generated in confluent cell monolayers and images were col-
lected at identical regions according to the time points specified. 
Wound healing areas were quantified using cellSens Dimension 
Software ver. 1.6 (Olympus). Data reflects triplicate measures 
from biological replicates.
Chemotherapy Dose–Response Assay
OV90 cells were transfected with siRNA as described above. 
However, transfected cells were incubated for 96  h following 
initial RNAi transfection before being plated equivalently in 
96-well plates and incubated overnight. Media was removed and 
replaced with fresh media containing dose titrations of cisplatin 
or paclitaxel. Cell viability was assessed 72  h later using the 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions; absorbance 
(490 nm) was measured using a microplate spectrophotometer 
(xMark, Bio-Rad) following incubation in MTS reagent at 
37°C. Two biological replicates were performed where each 
cisplatin and paclitaxel dose was assayed in triplicate for each 
experiment.
Immunoblot Analyses
Sub-confluent cells were lysed (1% SDS, 10 mM Tris–HCL pH 
7.4), and equivalent amounts of cell lysate were resolved on 
4–15% mini-PROTEIN TGX gels and transferred to PVDF 
membranes. Membranes were blocked for 1 h with 5% non-fat 
dry milk in 1× TBST and incubated with primary antibody 
overnight at 4°C. Secondary antibody was incubated for 3 h at 
ambient temperature followed by incubation in SuperSignal West 
FigUre 2 | elevated nUaK1 transcript expression is associated with 
poor progression-free survival in an independent cohort of  
high-grade serous ovarian cancer patients. Quantitative PCR analyses of 
formalin-fixed, paraffin-embedded tissues from advanced stage serous 
ovarian cancer patients exhibiting less than 2 years versus greater than or 
equal to 2 years progression-free survival (Student’s t-test p = 0.045). Data 
reflects triplicate, technical replicate analyses.
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Dura Chemiluminescent Substrate (ThermoFisher Scientific) 
for 5 min. Antibodies and concentrations were used as follow: 
anti-NUAK1 rabbit polyclonal (4458S, Cell Signaling, 1:1000), 
anti-GAPDH rabbit polyclonal (ab9485, Abcam, 1:1,000), and 
HRP-linked goat anti-rabbit IgG (Cell Signaling Technologies. 
1:1000). Images were acquired using a ChemiDoc XRS+ system 
(Bio-Rad).
resUlTs
association between elevated nUaK1 and 
Worse Os and PFs in serous Ovarian 
cancer Patients
NUAK1 transcript expression was assessed in a cohort of 1,262 
patients assembled from seven publicly available, ovarian 
cancer Affymetrix microarray data sets downloaded from the 
curatedOvarianData database (14) and an independent cohort 
of 174 HGSOC patients with Agilent gene expression data (8) 
(Table 1). Of the ovarian cancer patients with Affymetrix data, 
802 also had PFS data. PFS data was not available for the patients 
with Agilent data. Univariate and multivariate Cox regression 
modeling revealed that elevated NUAK1 transcript expression 
was associated with an increased risk of death in both cohorts 
(Table S1 in Supplementary Material) and disease progression 
in cohort with PFS data (Table S2 in Supplementary Material).
Women with transcript expression of NUAK1 categorized as 
high vs. low had worse OS (log-rank p < 0.0001), with a median 
survival difference of 10.5  months in high vs. low NUAK1-
expressing patients (Figure  1A, Figure S1 in Supplementary 
Material). Furthermore, elevated NUAK1 transcript expression 
was associated with poor PFS (p = 0.003), with a median survival 
difference of 4.5 months in patients with high vs. low NUAK1 
(Figure  1B). Consistent with these differences in OS and PFS, 
high vs. low NUAK1 indicated a significant unadjusted and 
stage-adjusted increased risk of death (Figure  1C) and disease 
progression (Figure 1D).
Quantitative PCR was performed in FFPE tissues from 
25 HGSOC patients with short PFS (<2  years) and 9 HGSOC 
patients with long PFS (>2 years). All patients were diagnosed 
with advanced-stage disease. HGSOC patients exhibiting PFS 
times of less than 2  years expressed higher NUAK1 transcript 
expression than that in patients who progressed more than 
2 years after diagnosis (p = 0.045, Figure 2).
relationship between elevated nUaK1 and 
Older age, advanced stage, any residual 
Disease and Mesenchymal subtype
Logistic regression modeling (Figure  3A; Table S3 in 
Supplementary Material) demonstrated a relationship between 
elevated NUAK1 expression and aggressive clinic-pathologic 
features, as well as select molecular subtypes in ovarian cancer 
patients, but not with BRCA1/2 status [odds ratio (OR) = 0.93, 
p > 0.05]. Elevated NUAK1 was associated with an increased risk 
of being diagnosed at an older age, categorized as < vs. ≥60 years 
old (OR = 1.23, p = 0.003) and at advanced stage (OR = 1.73, 
p < 0.0001) as well as with harboring residual disease following 
primary cytoreductive surgery (OR = 1.58, p < 0.0001). TCGA 
(5), Verhaak et al. (7), and Konecny et al. (8) developed inde-
pendent molecular classifiers for proliferative, mesenchymal, 
immunoreactive, and differentiated subtypes of SOC. NUAK1 
transcript expression was evaluated in the subset of 472 patients 
with the TCGA classification, 504 with the Verhaak classifica-
tion, and 182 with the Konecny classification to determine if 
NUAK1 varied in any of the molecular subtypes (Figures 3B,E). 
Elevated expression of NUAK1 was not consistently related to 
proliferative subtype (Figure  3B) or immunoreactive subtype 
(Figure 3D) but was consistently less common in patients with 
the differentiated subtype as defined by all three classifiers with 
ORs below 0.5 (Figure 3C, p < 0.0001) and more common in 
the TCGA-, Verhaak- and the Konecny-derived mesenchymal 
subtype with ORs that exceeded 2.0 (Figure 3E, p < 0.0001).
Downregulation of nUaK1 Does not 
sensitize sOc to cisplatin or Paclitaxel, 
but Does attenuate the Migratory 
Potential of chemosensitive and resistant 
Ovarian cancer cells In Vitro
To clarify the relationship between elevated NUAK1 and poor 
PFS, we performed in  vitro chemosensitization analyses in a 
model of HGSOC cells (OV90) (25) transfected with a small 
interfering RNA to silence NUAK1 expression followed by assess-
ment of cisplatin and paclitaxel dose–response (Figure S2A–C in 
Supplementary Material). These studies revealed that NUAK1 
knockdown had no significant impact on relative sensitivity to 
cisplatin or paclitaxel in OV90 cells.
As we found NUAK1 expression to be associated with both 
advanced stage and the mesenchymal subtype of HGSOC, we 
6Phippen et al. NUAK1 Impacts Prognosis in HGSOC
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hypothesized that elevated levels of the NUAK1 gene product 
may increase the migratory potential of HGSOC cells. To test 
this hypothesis, we silenced NUAK1 expression in OV90 cells 
(25) and in an in-house generated model of chemorefractory, 
high-grade HGSOC (E3 cells) (24). Cell lines were trans-
fected with a scrambled control siRNA (non-targeting, NT) 
or a NUAK1-specific siRNA, and NUAK1 knockdown was 
confirmed by immunoblot (Figure 4B). Immunoblot analyses 
revealed a discrete immunoreactive band for NUAK1 in E3 cells 
(Figure 4B), but a doublet in OV90 cells (Figure 4C), consist-
ent with previous evidence denoting tissue/cell type-specific 
immunoblot patterns for NUAK1 (26). Wound healing analyses 
of confluent monolayers of RNAi-transfected ovarian cells 
revealed significant decreases in migration in NUAK1-silenced 
cells (Figure  4A (E3 cells); Figures  4B,C). Notably, although 
the chemoresistant E3 cells were found to be highly migratory 
relative to OV90 cells (Figures  4B,C, hours after wounding), 
E3 cells exhibited a greater relative loss of migratory potential 
following NUAK1 knockdown (Figure  4B) as compared with 
OV90 cells (Figure 4C).
DiscUssiOn
Nua kinase 1 is a downstream effector of Akt and is activated 
in response to cellular hypoxia and nutrient starvation 
(10, 11). Elevated expression of NUAK1 leads to enhanced 
proliferation, invasion, and metastatic capabilities in diverse 
tumor cell types (10, 11). Using publicly available transcript 
expression data from 1,262 ovarian cancer patients, we show 
that elevated NUAK1 is associated with decreased OS and PFS. 
We were able to validate the relationship between NUAK1 
expression and OS in an independent cohort of 174 ovarian 
cancer patients with Agilent data. PFS data were, however, not 
available for the independent cohort with Agilent data. We 
turned to quantitative PCR in a small cohort of patients with 
advanced stage < or >2 years PFS to validate our finding that 
higher transcript expression of NUAK1 was associated with 
shorter PFS. The association between elevated NUAK1 expres-
sion with poor PFS from a publicly available cohort of 802 
patients was independently validated by quantitative PCR in 
an archival tissue set of 25 HGSOC patients with PFS <2 years 
and 9 HGSOC patients with PFS >2 years, following primary 
diagnosis. To explore the relationship of NUAK1 and PFS, we 
assessed whether NUAK1 contributed to chemosensitivity in 
a model of HGSOC cells (OV90). We silenced NUAK1 gene 
expression in OV90 cells by RNAi followed by treatment with 
cisplatin or paclitaxel and found that loss of NUAK1 did not 
impact chemosensitivity relative to control cells (Figure S2A–C 
in Supplementary Material).
We, further, observed that elevated NUAK1 is associated with 
increased odds of harboring residual disease (>R0) and present-
ing at advanced disease stage. Further, we found that elevated 
NUAK1 significantly correlates with the mesenchymal disease 
subtype (5, 7, 8). Previous assessments of molecular ovarian 
FigUre 3 | Odds ratios analyses of nUaK1 transcript expression relative to relevant clinicopathological criteria and molecular disease subtypes of 
high-grade serous ovarian cancer. Forest plots detailing odds ratio of patients exhibiting elevated NUAK1 transcript expression relative to clinic-pathological 
criteria and molecular disease subtypes in public gene expression data. Raw odds ratios results and patient cohorts available for analyses detailed in Table S3 in 
Supplementary Material.
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FigUre 4 | nUaK1 regulates the migratory potential of chemosensitive and chemoresistant high grade serous ovarian cancer cells. (a) Time-course 
wound healing assay micrographs of chemoresistant ovarian cancer cells (E3) following NUAK1 knockdown by small interfering RNA (siRNA). (B) Representative 
rates of wound healing in E3 cells following siRNA-mediated knockdown of NUAK1 (*Paired t-test p = 0.005734). (c) Representative rates of wound healing in 
chemosensitive ovarian cancer cells (OV90) following siRNA-mediated knockdown of NUAK1 (*Paired t-test p = 0.01315). Inset immunoblot images in (B,c) detail 
confirmation of NUAK1 knockdown. Data in (B,c) represent percent of wounds healed relative to areas measured at t = 0 h. Data points reflect duplicate, technical 
replicates, and data sets are representative of triplicate biological replicates.
cancer disease subtypes have found that mesenchymal-like 
disease is associated with a significantly increased risk of poor 
disease survival (8). Further, we provide functional evidence that 
NUAK1 regulates tumor cell migration in both chemosensitive 
(OV90) and chemoresistant (E3) ovarian cancer cell lines. These 
observations bear directly on the relevance of NUAK1 as a pos-
sible therapeutic target in patients that present with chemoresist-
ant or refractory disease. Our comparative analysis of NUAK1 
expression levels with relevant clinic-pathologic measures of 
metastatic spread and patient tumor burden, as well as in vitro 
cell migratory analyses in chemo-sensitive and -resistant models 
of ovarian cancer cells, confirms previous findings implicating 
NUAK1 as a key factor supporting invasive and metastatic 
characteristics of tumor cells.
Overall, our findings corroborate previous evidence that 
has implicated NUAK1 as a key factor underlying poor disease 
prognosis in diverse cancer subtypes and expand on recent 
precedents associating NUAK1 transcript expression with poor 
outcome in HGSOC patients. Additional studies are required to 
further the clinical development and deployment of NUAK1 in 
HGSOC, and to determine the utility of NUAK1 as a potential 
therapeutic target to mitigate disease progression in HGSOC 
patients.
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